Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysema
Authors:
- Masayuki HanaokaMHMasayuki Hanaoka
- Ping ChenPCPing Chen
- Yunden DromaYDYunden Droma
- Norbert F. VoelkelNVNorbert F. Voelkel
- Keishi KuboKKKeishi Kubo
Open Access
- 1 April 2009
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 296 (4) , L648-L656
Abstract
Chronic inflammation, imbalance of proteolytic and anti-proteolytic activities, oxidative stress, and apoptosis of lung structural cells contribute to the pathogenesis of COPD. Prostacyclin protects cells against apoptosis, has anti-inflammatory properties, partially prevents cigarette smoke extract (CSE)-induced apoptosis of the pulmonary endothelium, and thus may be relevant in the pathogenesis of emphysema. We determined whether a synthetic stable prostacyclin analog, beraprost sodium (BPS), attenuates the development of CSE-induced emphysema and elucidated the molecular mechanisms involved in its effect. Sprague-Dawley rats were treated with BPS and injected with CSE once a week for 3 wk. We measured the DNA damage of cells, the expression of caspase-3, and the activity of matrix metalloproteinase (MMP)-2 and MMP-9. We also analyzed TNFα and IL-1β concentrations and the serum antioxidant activity. BPS prevented the development of CSE-induced emphysema, resulting in significant attenuation in alveolar enlargement and pulmonary parenchymal destruction. BPS inhibited pulmonary apoptosis and induction of MMP-2 and MMP-9 activity. Moreover, the protective effect of BPS was associated with a reduction of the expression of proinflammatory cytokines including TNFα and IL-1β and a normalized biological oxidant activity. BPS introduces all these events, probably by activating cAMP signaling through acting specific prostacyclin receptors. In conclusion, BPS protects against the development of CSE-induced emphysema by attenuating apoptosis, inhibiting proteolytic enzyme activity, reducing inflammatory cytokine levels, and augmenting antioxidant activity. BPS may potentially represent a new therapeutic option in the prevention of emphysema in humans in prospect.Keywords
This publication has 34 references indexed in Scilit:
- Prostacyclin Analogs Inhibit Fibroblast Contraction of Collagen Gels through the cAMP-PKA PathwayAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Prostacyclin Prevents Pulmonary Endothelial Cell Apoptosis Induced by Cigarette SmokeAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in ratsBiochemical and Biophysical Research Communications, 2006
- Activated Oligoclonal CD4+ T Cells in the Lungs of Patients with Severe EmphysemaProceedings of the American Thoracic Society, 2006
- Repeated cadmium nebulizations induce pulmonary MMP-2 and MMP-9 production and enphysema in ratsToxicology, 2005
- Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptorAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cellsImmunology & Cell Biology, 2003
- A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in ratsJACC, 2002
- Protective Effect of Beraprost Sodium, a Stable Prostacyclin Analogue, in Development of Monocrotaline-Induced Pulmonary HypertensionJournal of Cardiovascular Pharmacology, 1996
- Prostacyclin (PGI2) Synthase Is a Constitutively Expressed Enzyme in Human Endothelial CellsExperimental Cell Research, 1995